Top Story

Iluvien earns marketing authorization in Ireland

November 26, 2014

Alimera Sciences announced that marketing authorization has been granted to Iluvien in Ireland.

Through the repeat use application procedure, the Irish Health Products Regulatory Authority granted marketing authorization to Iluvien (fluocinolone acetonide intravitreal implant) for the treatment of vision impairment associated with chronic diabetic macular edema that is unresponsive to available therapies, according to a company press release.

Prakash Nagarkatti, PhD Meeting News Coverage

Speakers share latest research on cannabinoids

November 18, 2014
DENVER – Three presenters here at the American Academy of Optometry plenary session discussed the dangers of recreational use of cannabinoids and the potential…

Iluvien receives marketing authorization in Belgium

November 13, 2014
The Belgian Federal Agency for Medicines and Health Products has granted marketing approval for Iluvien to treat impaired vision associated with chronic diabetic macular…

See what PCON bloggers are saying this week

November 7, 2014
All five Primary Care Optometry News bloggers posted new entries within the past week. Topics cover age-related macular degeneration, health care reform, technology…
CME
Postoperative Inflammation and Pain

Postoperative Inflammation and Pain: Elimination of the Dynamic Duo to Improve Patient Outcomes

This activity is supported by an educational grant from Bausch + Lomb.

Cataract surgery has improved in both safety and outcomes in recent years. With advances in surgical techniques…
More »
Meeting News Coverage Video
Chet Kumar th

FDA expands indication for implantable miniature telescope

CHICAGO – At the American Academy of Ophthalmology, Chet Kumar, vice president of sales and market development…
More »

Iluvien earns marketing authorization in Ireland

November 26, 2014
Alimera Sciences announced that marketing authorization has been granted to Iluvien in Ireland.Through the repeat use application procedure, the…
Prakash Nagarkatti, PhD Meeting News Coverage

Speakers share latest research on cannabinoids

November 18, 2014
DENVER – Three presenters here at the American Academy of Optometry plenary session discussed the dangers of recreational use of cannabinoids…

Iluvien receives marketing authorization in Belgium

November 13, 2014
The Belgian Federal Agency for Medicines and Health Products has granted marketing approval for Iluvien to treat impaired vision associated with…

See what PCON bloggers are saying this week

November 7, 2014
All five Primary Care Optometry News bloggers posted new entries within the past week. Topics cover age-related macular degeneration, health care…

CMS to reimburse VisionCare’s implantable miniature telescope

November 4, 2014
VisionCare Ophthalmic Technologies has announced that the Centers for Medicare and Medicaid Services will reimburse the company’s implantable…

Pre-AMD: Duty to warn?

November 3, 2014
In my last post a few weeks ago I used the term “pre-AMD.” I love this term. I have been using it since Vision Expo West, when I first…
Cover Photo PCON Reports

Experts agree on need to standardize testing for contact lens products

Primary Care Optometry News, November 2014
Most scientific experts concur that existing testing methods for contact lenses and solutions should be reviewed. In September, the U.S. Food and…
New report finds risk of optometrist shortage

New report finds risk of optometrist shortage

Primary Care Optometry News, November 2014
Optometry is one of the health professions most at risk for a workforce deficit in the future, according to a study recently released by the…
Workshop participants take steps to address MK From The Editor

Workshop participants take steps to address MK

Primary Care Optometry News, November 2014
Michael D. DePaolis, OD, FAAO
One of the great features of Healio.com is the ability to access so much contemporary information across so many medical disciplines. Among the…
John Hovanesian th Video

Omeros granted CMS pass-through reimbursement status for Omidria

October 31, 2014
The Center for Medicare and Medicaid Services has granted Omeros Corporation with transitional pass-through status for Omidria 1%/0.3%, according to…
More Headlines »
morganatic-roan
morganatic-roan